Tapaninen T - Search Results

1

Genomewide Association Study of Simvastatin Pharmacokinetics.

Mykkänen AJH, Taskinen S, Neuvonen M, Paile-Hyvärinen M, Tarkiainen EK, Lilius T, Tapaninen T, Backman JT, Tornio A, Niemi M. Mykkänen AJH, et al. Among authors: tapaninen t. Clin Pharmacol Ther. 2022 Sep;112(3):676-686. doi: 10.1002/cpt.2674. Epub 2022 Jun 24. Clin Pharmacol Ther. 2022. PMID: 35652242 Free PMC article.

2

Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren.

Tapaninen T, Neuvonen PJ, Niemi M. Tapaninen T, et al. Eur J Clin Pharmacol. 2010 May;66(5):497-502. doi: 10.1007/s00228-010-0796-3. Epub 2010 Feb 24. Eur J Clin Pharmacol. 2010. PMID: 20179914 Clinical Trial.

3

Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.

Tapaninen T, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M. Tapaninen T, et al. J Clin Pharmacol. 2011 Mar;51(3):359-67. doi: 10.1177/0091270010365885. Epub 2010 Apr 16. J Clin Pharmacol. 2011. PMID: 20400651 Clinical Trial.

4

Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren.

Tapaninen T, Neuvonen PJ, Niemi M. Tapaninen T, et al. Eur J Clin Pharmacol. 2010 Sep;66(9):865-70. doi: 10.1007/s00228-010-0836-z. Epub 2010 May 23. Eur J Clin Pharmacol. 2010. PMID: 20496145

5

Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren.

Tapaninen T, Neuvonen PJ, Niemi M. Tapaninen T, et al. Clin Pharmacol Ther. 2010 Sep;88(3):339-42. doi: 10.1038/clpt.2010.101. Epub 2010 Jul 21. Clin Pharmacol Ther. 2010. PMID: 20664534 Clinical Trial.

6

Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren.

Tapaninen T, Neuvonen PJ, Niemi M. Tapaninen T, et al. Br J Clin Pharmacol. 2011 May;71(5):718-26. doi: 10.1111/j.1365-2125.2010.03898.x. Br J Clin Pharmacol. 2011. PMID: 21204914 Free PMC article. Clinical Trial.

7

SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren.

Tapaninen T, Karonen T, Backman JT, Neuvonen PJ, Niemi M. Tapaninen T, et al. Pharmacogenet Genomics. 2013 Jan;23(1):19-24. doi: 10.1097/FPC.0b013e32835bac90. Pharmacogenet Genomics. 2013. PMID: 23151832

8

Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions.

Tornio A, Filppula AM, Kailari O, Neuvonen M, Nyrönen TH, Tapaninen T, Neuvonen PJ, Niemi M, Backman JT. Tornio A, et al. Among authors: tapaninen t. Clin Pharmacol Ther. 2014 Oct;96(4):498-507. doi: 10.1038/clpt.2014.141. Epub 2014 Jun 27. Clin Pharmacol Ther. 2014. PMID: 24971633 Clinical Trial.

9

Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics.

Hirvensalo P, Tornio A, Neuvonen M, Tapaninen T, Paile-Hyvärinen M, Kärjä V, Männistö VT, Pihlajamäki J, Backman JT, Niemi M. Hirvensalo P, et al. Among authors: tapaninen t. Clin Pharmacol Ther. 2018 Jul;104(1):158-168. doi: 10.1002/cpt.891. Epub 2017 Nov 6. Clin Pharmacol Ther. 2018. PMID: 28940478 Free PMC article.

10

Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects.

Neuvonen M, Tarkiainen EK, Tornio A, Hirvensalo P, Tapaninen T, Paile-Hyvärinen M, Itkonen MK, Holmberg MT, Kärjä V, Männistö VT, Neuvonen PJ, Pihlajamäki J, Backman JT, Niemi M. Neuvonen M, et al. Among authors: tapaninen t. Basic Clin Pharmacol Toxicol. 2018 Mar;122(3):341-345. doi: 10.1111/bcpt.12916. Epub 2017 Nov 17. Basic Clin Pharmacol Toxicol. 2018. PMID: 28990360 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

22 results

Search Page